Jeffrey L Brown

Summary

Affiliation: AstraZeneca R and D

Publications

  1. ncbi A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models
    Jeffrey L Brown
    AstraZeneca Pharmaceuticals, Waltham, Massachusetts, USA
    Mol Cancer Ther 9:145-56. 2010

Detail Information

Publications1

  1. ncbi A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models
    Jeffrey L Brown
    AstraZeneca Pharmaceuticals, Waltham, Massachusetts, USA
    Mol Cancer Ther 9:145-56. 2010
    ..These studies provide preclinical data for 3.19.3 as a potential new antiangiogenic therapy as a single agent or in combination with chemotherapy or vascular endothelial growth factor inhibitors for the treatment of cancer...